Colloques du Collège de France - Collège de France

Edith Heard

Collège de France

Epigénétique et mémoire cellulaire

Année 2024-2025

Colloque - L'inactivation du chromosome X : HCFC1, a novel activator of XCI

Organisation : Pre Edith Heard (Collège de France, chaire Épigénétique et mémoire cellulaire) et Pre Claire Rougeulle (Institut Curie)

Hegias Mira Bontenbal

Erasmus, Pays-Bas

Edith Heard

Collège de France

Epigénétique et mémoire cellulaire

Année 2024-2025

Colloque - L'inactivation du chromosome X : The impact of sex chromosomes on the mouse preimplantation embryo

Organisation : Pre Edith Heard (Collège de France, chaire Épigénétique et mémoire cellulaire) et Pre Claire Rougeulle (Institut Curie)

Daniel Snell

Crick Institute, Royaume-Uni

Edith Heard

Collège de France

Epigénétique et mémoire cellulaire

Année 2024-2025

Colloque - L'inactivation du chromosome X : L'inactivation du chromosome X

Organisation : Pre Edith Heard (Collège de France, chaire Épigénétique et mémoire cellulaire) et Pre Claire Rougeulle (Institut Curie)

Osamu Masui

Riken, Japon

Edith Heard

Collège de France

Epigénétique et mémoire cellulaire

Année 2024-2025

Colloque - L'inactivation du chromosome X : Escape from X-inactivation is directly modulated by Xist RNA levels

Organisation : Pre Edith Heard (Collège de France, chaire Épigénétique et mémoire cellulaire) et Pre Claire Rougeulle (Institut Curie)

Agnese Loda

EMBL, Allemagne

Edith Heard

Collège de France

Epigénétique et mémoire cellulaire

Année 2024-2025

Colloque : L'inactivation du chromosome X

Organisation : Pre Edith Heard (Collège de France, chaire Épigénétique et mémoire cellulaire) et Pre Claire Rougeulle (Institut Curie)

Edith Heard

Professeur du Collège de France

Claire Rougeulle

Institut Curie

Sébastien Lecommandoux

Collège de France

Innovation technologique Liliane Bettencourt (2024-2025)

Année 2024-2025

Colloque - Advancing Biomaterials: Biomimetic and Biohybrid Innovations

Sébastien Lecommandoux : Biohybrid and Dynamic Polymersomes: from Precision Therapy to Artificial Cells

Sébastien Lecommandoux

Enseignant-chercheur au Laboratoire de chimie des polymères organiques, Bordeaux INP, professeur invité du Collège de France

Sébastien Lecommandoux

Collège de France

Innovation technologique Liliane Bettencourt (2024-2025)

Année 2024-2025

Colloque - Advancing Biomaterials: Biomimetic and Biohybrid Innovations

Molly Stevens : Designing and translating new materials for advanced therapies and disease detection

Molly Stevens

John Black Professor of Bionanoscience, University of Oxford

Résumé

This talk will present recent advances in therapeutic and biosensing materials, with a focus on translational pipelines for clinical application. We have developed scalable fabrication methods to create complex 3D architectures and biofunctionalized surfaces with spatially organized biochemical and topographical cues. Our delivery platforms include high-molecular-weight polymer carriers for saRNA therapeutics and photo-responsive nanoreactors inspired by circadian rhythms. We are also exploring bioinspired soft robotics for targeted, stimuli-responsive drug delivery.

In diagnostics, we are engineering functionalized nanoparticles for in vivo disease detection, including colorimetric nanoprobes for visual readouts and CRISPR-based, preamplification-free RNA detection (CrisprZyme). We have developed Raman microspectroscopy tools and machine learning techniques for hyperspectral unmixing, enabling the analysis of live-cell and organoid models and tracking nanomedicines in vivo.

A key innovation is our SPARTA™ platform, which enables high-throughput, label-free characterization of single nanoparticles, supporting the development of nanoparticle therapeutics and exosome diagnostics.

This talk will explore how these technologies are advancing biomedical innovation and how we are establishing translational pathways to bring them into the clinic—while striving to make healthcare solutions more accessible and equitable.

Molly Stevens

Professor Dame Molly Stevens FREng FRS is John Black Professor of Bionanoscience at the University of Oxford (Department of Physiology, Anatomy and Genetics and Institute of Biomedical Engineering) and part-time Professor at Imperial College London and the Karolinska Institute.

Professor Stevens' multidisciplinary research balances the investigation of fundamental science with the development of technologies and designer biomaterials to address some of the major healthcare challenges across diagnostics, advanced therapeutics and regenerative medicine. The impact of her work is recognised by numerous accolades, including the 2023 Novonordisk Prize.

Professor Stevens' work has a strong translational drive, focussed on translating scientific innovation into practical solutions to benefit patients and society. She is a serial entrepreneur and the founder of four spin-off companies in the diagnostics, advanced therapeutics, and regenerative medicine space. She has been recently appointed as Oxford University Champion for Women and Diversity in Entrepreneurships.

Sébastien Lecommandoux

Collège de France

Innovation technologique Liliane Bettencourt (2024-2025)

Année 2024-2025

Colloque - Advancing Biomaterials: Biomimetic and Biohybrid Innovations

Timothy J. Deming : Enhancing biomimicry via polypeptide side-chain modifications

Timothy J. Deming

Professeur, UCLA

Résumé

Our lab has pursued development of methods to allow selective incorporation of diverse functionality into synthetic polypeptide materials. Specifically, we have developed synthetic methods that allow a robust variety of modifications to nucleophilic thioether containing side-chains in both methionine and alkylated cysteine residues. Here we show such modifications can create synthetic polypeptides that can mimic environmentally responsive coacervate formation as has been observed in cytosolic proteins. We also show how modifications can be performed simultaneously on both segments of aqueous block copolymer assemblies resulting in materials that can respond to biologically relevant stimuli.

Timothy J. Deming

Timothy J. Deming received a B.S. in Chemistry from the University of California, Irvine in 1989, and graduated with a Ph.D. in Chemistry from the University of California, Berkeley, in 1993. After a NIH postdoctoral fellowship at the University of Massachusetts, Amherst with David Tirrell, he joined the faculty in the Materials Department at the University of California, Santa Barbara in 1995. Here he held appointments in the Materials and Chemistry Departments where he was promoted to Associate Professor in 1999 and Full Professor in 2003. His appointment is now as Distinguished Professor of Bioengineering and Chemistry and Biochemistry at the University of California Los Angeles. He served as the Chairman of the Bioengineering Department at UCLA from 2006 to 2011. He is a leader in the fields of polypeptide synthesis, self-assembly of block copolypeptides, and use of polypeptides in biology, for which he has received awards from the National Science Foundation, the Office of Naval Research, The Arnold and Mabel Beckman Foundation, the Alfred P. Sloan Foundation, the Camille and Henry Dreyfus Foundation, the Materials Research Society, and the IUPAC Macromolecular Division. He is also a Fellow of the American Institute of Medical and Biological Engineering, and recently received the Fulbright-Tocqueville Distinguished Chair Award. Professor Deming has a long track record of training students for performing ethical, rigorous research and for organizing their data for presentations and publications. He is active in the bioinspired materials community, recently served as an Associate Editor for Biomacromolecules, and has been an Editorial Advisory Board member for Macromolecular Bioscience, Soft Matter, Macromolecules, and Biopolymers.

Sébastien Lecommandoux

Collège de France

Innovation technologique Liliane Bettencourt (2024-2025)

Année 2024-2025

Colloque - Advancing Biomaterials: Biomimetic and Biohybrid Innovations

Raffaele Mezzenga : Amyloid-metal biohybrids for health and environmental remediation

Raffaele Mezzenga

Professeur, ETH Zurich

Résumé

Amyloid fibrils interact with metal ions via metal-ligand supramolecular interactions whose energy is of the order of tens to hundreds of KBT. The occurrence of the 20 essential amino acids in food-based amyloid fibrils derived from inexpensive animal and plant proteins, including from food waste, combined with the extreme aspect ratio of the amyloids, allow for an affordable, yet universal toolbox to produce multifunctional hybrids which can serve in a multitude of applications and technologies. In this talk I will provide several examples of food amyloid fibrils interacting with metal ions and nanoparticles for both health and environmental remediation, some of which have made it into real technologies. Taking β-lactoglobulin amyloids as a model amyloid system derived from whey, a by-product of cheese making process, I will show how metal ions can be adsorbed from water and wastewater solutions by amyloid-based filters for water purification purposes, or how gold ions can be adsorbed and processed from amyloid aerogels to recycle gold from e-waste. I will also show how iron atoms can be coordinated to β-lactoglobulin amyloids to deliver highly bioavailable Fe(II) for iron fortification, or to design hydrogels capable of performing cascade enzymatic reactions for alcohol detoxification in vivo.

Raffaele Mezzenga

Raffaele Mezzenga is full professor at ETH Zurich since 2009. His research focuses on the self-assembly of proteins, polymers, liquid crystals, food and colloidal systems. He is a Highly Cited Researcher (Clarivate, 2023) in the cross-field discipline, with more than 450 publications and 20 patents. His work has been recognized by several prestigious international distinctions such as the 2017 Fellowship and the 2013 Dillon Medal by the American Physical Society, the 2013 Biomacromolecules/Macromolecules Young Investigator Award by the American Chemical Society, the 2011 American Oil Chemists' Society Young Scientist Research Award, and the 2004 Swiss Science National Foundation Professorship Award.

Sébastien Lecommandoux

Collège de France

Innovation technologique Liliane Bettencourt (2024-2025)

Année 2024-2025

Colloque - Advancing Biomaterials: Biomimetic and Biohybrid Innovations

María J. Vicent : Polypeptide-Based Nanomedicines: Enhancing Tropism and Overcoming Biological Barriers

María J. Vicent

Professeur, CIPF Valence

Résumé

Polypeptides play a crucial role in areas like nanomedicine, where their biological function is governed by intricate structural features. Studying structure-activity relationships is essential to optimize polypeptide-conjugate designs, as minor structural changes can lead to unexpected yet highly effective biological outcomes. We have addressed traditional synthetic limitations by using controlled NCA polymerization and rigorous characterization, producing well-defined architectures. Post-polymerization modifications introduce various functional groups and orthogonal reactive sites, enabling a wide range of polypeptide configurations, such as diblock copolymers and star-shaped structures. These can self-assemble into supramolecular nanostructures with unique biological properties, including tissue specificity, subcellular targeting, and potential brain delivery. Through a bottom-up strategy and the strategic design of polymer-drug linkers, in vitro and in vivo assessments have shown these systems to be non-toxic, with enhanced cellular uptake and extended half-life and accumulation in specific tissues like lymph nodes, mitochondria, and the brain. These findings position our polypeptide-based nanosystems as promising therapeutics.

María J. Vicent

Professor María J. Vicent leads the Polymer Therapeutics Lab at the Príncipe Felipe Research Center (CIPF) since 2006 and became its Scientific Director and Cancer Program Coordinator in 2024. She also oversees the Screening Platform, part of the EU-OpenScreen infrastructure, and currently serves as president-elect of the Controlled Release Society (CRS). Additionally, she is Editor-in-Chief of Advanced Drug Delivery Reviews. Her research focuses on designing innovative nanopharmaceuticals through Polymer Therapeutics to address unmet clinical needs in diagnostics and therapy. Her work has been supported by national and EU grants, including ERC-funded projects like MyNano, Polymmune, and Polybraint, as well as NanoPanTher and other public-private initiatives. María has received multiple accolades such as the Idea and Samyang awards and Women in Science honors. She is a Fellow of the National Academy of Inventors (FNAI), the AIMBE College of Fellows (since 2019), and the CRS College of Fellows (since 2021). With over 155 peer-reviewed publications and 15 patents, her innovations have led to six technology licenses, one of which helped launch the spin-off Polypeptide Therapeutic Solutions S.L. in 2012. The company, rebranded as Curapath after its acquisition by Arcline in 2021, is now a leading CDMO with over 100 employees.